Jim Cramer's 'Mad Money' Recap: Got Growth?

Tickers in this article: AA ACOR COP CRZO EOG FB KORS LCC MRK MTDR PBR REGN RMBS RRGB S SBAC SBUX T TMUS URI VZ WDC YELP
Search Jim Cramer's "Mad Money" trading recommendations using our exclusive "Mad Money" Stock Screener.


NEW YORK (TheStreet) -- Where can investors find the best growth stocks? All over place, if you know where to look, Jim Cramer said on "Mad Money" Tuesday.

In the biotech space, Cramer called out Regeneron as one such stock -- it has growth today and, thanks to a robust pipeline of new drugs, for many years to come. The oil patch is littered with high-growth stocks, including EOG Resources , Cramer continued.

Restaurants Red Robin Gourmet Burgers and Starbucks both have growth, as do retailers Michael Kors , which delivered a 49% increase in profits and a 23% increase in sales this quarter.

Cramer said just about any stock that deals with mobile, social media or the cloud is growing like gangbusters -- which leads right to this week's Twitter IPO. Just a few weeks ago, Cramer noted, he was at the high end of the range, saying Twitter could be worth up to $20 billion. But today, despite nothing factually changing, $20 billion seems at the low end of the range, with some calling for valuations as high as $50 billion for Twitter.

Cramer said that's a recipe for investors to get hurt, a la the Facebook IPO last year. He cautioned that the big boys are betting big that uninformed investors will be willing to pay anything for shares of Twitter -- which is why he's once again reminding everyone there are prices at which every stock just becomes uninvestable.

Cramer said he's willing to pay up to $28 a share for Twitter and not a penny more.

Executive Decision:

In the "Executive Decision" segment, Cramer sat down with Dr. Ron Cohen, president and CEO of Acorda Therapeutics , a stock that's up 31% so far in 2013 and just delivered a 16-cents-a-share earnings beat.

Cohen said sales of Acorda's multiple sclerosis drug, Ampyra, is the engine that's helping to drive the company forward and Acorda is very fortunate to have such a successful product. Acorda is not a one-hit wonder, however, as the company now has six drugs in clinical studies, including new formulations of ingredients of Amypra that may treat strokes and other conditions.